Landos Biopharma Inc (LABP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,897 | -21,935 | -15,816 | -9,956 | -6,034 |
| Depreciation Amortization | N/A | 44 | 44 | 47 | 32 |
| Accounts payable and accrued liabilities | 187 | -2,129 | -2,372 | -2,475 | -1,265 |
| Other Working Capital | 139 | 443 | -462 | -3,849 | -2,392 |
| Other Operating Activity | 73 | 3,100 | 3,098 | 2,953 | 1,489 |
| Operating Cash Flow | $-8,498 | $-20,477 | $-15,508 | $-13,280 | $-8,170 |
| Cash Flows From Investing Activities | |||||
| Sale Of Investment | N/A | 7,775 | 7,712 | 7,078 | 3,104 |
| Investing Cash Flow | $N/A | $7,775 | $7,712 | $7,078 | $3,104 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 16,567 | 16,567 | 16,567 | 16,666 |
| Common Stock Repurchased | N/A | -3,000 | -3,000 | -3,000 | -3,000 |
| Financing Cash Flow | $N/A | $13,567 | $13,567 | $13,567 | $13,666 |
| Exchange Rate Effect | 3 | 44 | 47 | 44 | 4 |
| Beginning Cash Position | 37,549 | 36,640 | 36,640 | 36,640 | 36,640 |
| End Cash Position | 29,054 | 37,549 | 42,458 | 44,049 | 45,244 |
| Net Cash Flow | $-8,495 | $909 | $5,818 | $7,409 | $8,604 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,498 | -20,477 | -15,508 | -13,280 | -8,170 |
| Free Cash Flow | -8,498 | -20,477 | -15,508 | -13,280 | -8,170 |